Volcano Corp. Misses by a Penny - Analyst Blog
May 03 2012 - 7:30AM
Zacks
Volcano
Corporation (VOLC) reported break-even earnings in the
first quarter of fiscal 2012, lagging behind the Zacks Consensus
Estimate by a penny and the year-ago quarter’s EPS of 2 cents.
Revenues for the quarter climbed 12% year over year to $90.4
million, nominally missing the Zacks Consensus Estimate of $91
million.
Revenues in the Medical segment
increased 15% during the quarter to $88.4 million on the back of a
37% growth in FFR (Fractional Flow Reserve) disposable business and
a 12% rise in IVUS (intravascular ultrasound) disposables business.
However, performance of the Industrial segment remained challenging
due to softness in telecom infrastructure spending in key
geographies. This resulted in a 48% year-over-year decline in
Industrial revenues to $2 million in the first quarter.
Management is impressed with the
overall performance in US and Japan. Over the past few quarters,
the company has been benefiting from a growing volume of data
depicting improved patient outcomes and economic benefits from the
use of functional percutaneous interventional (“PCI”) and the use
of intravascular guidance to optimize and confirm the therapy
during the procedure.
The European market recorded a
decline of 2% in IVUS disposable sales, with US and Japan recording
growth rates of 8% and 20%, respectively. The robust growth in
Japan, the largest IVUS market in the world, is gratifying as
Volcano Corporation has been trying to increase its penetration in
the country through direct sales program and/or introduction of new
products. The decline in Europe was due to a slowing economy and
earlier-than-expected decision to go direct in Spain.
Volcano Corporation recorded gross
margin of 67.3% in the quarter compared with 65.6% in the first
quarter of 2011. However, with both selling, general and
administrative, and research and development (R&D) expenses
increasing by 25% to $44.3 million and 4.3% to $13.6 million,
respectively, the company recorded a 250 basis point drop in
operating margin to 3.1% (excluding amortization of
intangibles).
Outlook
Volcano Corporation reiterated its
outlook for fiscal 2012. The company still expects to report
revenues of $392–$399 million (growth of 14–16% or 15–17% at
constant currency) and EPS of 21–24 cents. The current Zacks
Consensus Estimate of $395 million in revenues and EPS of 22 cents
is within the company’s guidance. Gross margin is expected around
64–-65% with operating expenses coming in at 57−58% of
revenues.
Recommendation
Volcano Corporation continues to
execute strategies to drive sales in the IVUS/FM markets backed by
new product launches and product enhancements. The company has been
expanding its presence in Japan through a direct sales program and
introduction of new products. The company is also benefiting from
the transition of its distribution agreement with Johnson
& Johnson (JNJ) that has enabled it to address 100% of
the business on a direct basis. Over the long term, the company
should benefit from this move as Japan has the largest IVUS market
in the world.
However, we are disappointed with
the decline in operating margin that has adversely affected the
company’s bottom line. We believe the rise in expenses is primarily
to support the various pipeline developmental programs and related
to the transition to a direct sales force in Spain.
Capital spending by hospitals has
been affected by the weak economy. Moreover, the company witnesses
stiff competition from players such as St Jude
Medical (STJ) and Boston Scientific
Corporation (BSX).
The stock carries a Zacks #3 Rank
(“Hold”) in the short term. Over the long term, we maintain our
Neutral recommendation on Volcano Corporation.
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
ST JUDE MEDICAL (STJ): Free Stock Analysis Report
VOLCANO CORP (VOLC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
(MM) (NASDAQ:VOLC)
Historical Stock Chart
From Jun 2024 to Jul 2024
(MM) (NASDAQ:VOLC)
Historical Stock Chart
From Jul 2023 to Jul 2024